The Role of Fibrocytes in Acute Lung Injury

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Taipei Medical University WanFang Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01373203
First received: June 13, 2011
Last updated: NA
Last verified: June 2011
History: No changes posted
  Purpose

The important character of acute lung injury (ALI) is alveolar capillary membrane damage caused by different diseases, such as sepsis, trauma and shock. One of the important pathological stages is the varying degrees of interstitial fibrosis and semi-permeable alveolar membrane fibrosis. It has been proved that CXCL12/SDF-1 (stromal cell-derived factor-1) induces fibrocyte migration, and promotes fibrosis progression. Study indicated that inhibition of TLR4 receptor signaling pathway improves fibrosis progression induced by ALI, however, the role of fibrocyte in ALI is still unclear. The fibrocytes was significantly increased in asthmatic patients with pulmonary fibrosis, which companies with increased CTGF expression. Therefore, this project assumes that fibrocyte will differentiation to fibroblast/myofibroblast in patient with acute lung injury, which in turn leads to progression of fibrosis. The central hypothesis of this project is that peripheral progenitor cell fibrocytes play an important role in alveolitis caused by acute lung injury. The overall objective of this project is to study the role of fibrocytes in acute lung injury.


Condition
Acute Lung Injury(ALI)

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: The Role of Fibrocytes in Acute Lung Injury

Resource links provided by NLM:


Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 20
Study Start Date: January 2011
Estimated Study Completion Date: December 2011
  Eligibility

Ages Eligible for Study:   20 Years and older
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Acute Lung Injury patients

Criteria

Inclusion Criteria:

  • Acute Lung Injury patients
  • Above 20 years old
  • Bilateral lung infiltrates
  • PaO2/FiO2<300mmHg
  • PCWP<18mmHg

Exclusion Criteria:

  • Pregnant women
  • Under 20 years old
  • Hb<8.0mg/dl
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01373203

Locations
Taiwan
Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Kuan-Jen Bai Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Kuan-Jen Bai, Division of Pulmonary & Critical Care Medicine
ClinicalTrials.gov Identifier: NCT01373203     History of Changes
Other Study ID Numbers: 99077
Study First Received: June 13, 2011
Last Updated: June 13, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
Acute Lung Injury(ALI)

Additional relevant MeSH terms:
Lung Injury
Acute Lung Injury
Respiratory Distress Syndrome, Adult
Lung Diseases
Respiratory Tract Diseases
Thoracic Injuries
Wounds and Injuries
Respiration Disorders

ClinicalTrials.gov processed this record on September 18, 2014